Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-025-62925-1
Affiliations:
3
Authors:
14
Go to article
Institutions Authors Share
Argenx SE, Belgium
11.000000
11.000000
 0.79
Aarhus University (AU), Denmark
2.000000
 0.14
Curare Consulting BV, Netherlands
1.000000
 0.07
Interested in Immunology?